ISR - Earnings call transcript Q2 2019 | Perspective Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day ladies and gentlemen and welcome to the IsoRay Second Quarter 2019 Call. All lines have been placed on a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructions]. At this time, it is my pleasure to turn the floor over to your host, Mark Levin.

Mark Levin

Thank you, Operator. you quarter us the XXXX December XXXX. thank IsoRay for quarter and XX, second fiscal earnings afternoon for today joining the ended Good call for

to similar and expressions within or company’s I and they this as available will, relate in call well amended. Securities company believe, of this encourage, forward-looking Private the expect, the constitute the the as its in a Private Before Securities the as Litigation to Certain anticipate, within statements conference to will of identify conference statements When management such of get assumptions information Reform forward-looking statements. as used meaning started, few XXXX. we as, management call Act made XXXX minutes meaning by currently of read forward-looking Litigation the statements Act take words the Reform

current are based on statements Forward-looking and management’s events. future beliefs about expectations

forecast and obligation and inherently alter any are susceptible new whether projection with its and forward-looking expressly uncertainty or to company or the to disclaims events such any otherwise. statements to update As information, changes from obligation circumstances or they undertakes in resulting changes subsequent no

of forward-looking risk February company's Securities of the contained is harbor statement today, XX, Commission. Statements in safe Exchange and XXXX. call for Additional under as filings today's concerning factors information are time-to-time statements from the listed heading the with on made

Chief then Executive We financial will Hunt, And quarter IsoRay's the Chief call Officer. will results. Woods, today's discuss Financial second fiscal begin Lori with IsoRay's Jonathan Officer

will over I questions prepared analysts remarks institutional our to now investors. the their will turn take call from Following we Lori Woods. and

Lori Woods

to us a thank I and afternoon months IsoRay When Good today. commitment ago, rejoined I Mark. you for six you, joining made progress. Thank

market plan increasing and expanding part for on unwavering and factors this quarter important have shareholder key future statement. growth. including an concentrating makes focus believe listed value revenue, on an opportunity I the of I and been the As

consecutive seventh this from growth report quarter ending of XX% double-digit to year quarter excited our up are We the period. revenue ago

included Build we XX% the increased accomplish creating limited quarter for our Our core record Blu capacity and and brachytherapy have system, able revenue which year-over-year we company's The to what been from prostate this contribution and our sales quarter. core prostate underscore business. launched sustaining in during momentum a delivery

Just Cancer numbers as and importantly, press treated the innovative across a delivery using since Marshall has Cesium-XXX. Hollings for view that opportunities what Recently it patient and by the interest and heightened Blu first It among an to Clearly, system country. contribute awareness treating the very patients the expanded by becomes for the of our patient. quarter getting are of been increased the of it s and clear use positive a interest benefits market subsequent this adoption. testament its offers quarter's acceptance demonstrated for David each believe prestigious Dr. we a where Dr. Build with are Blu distributed response as additional clinicians first our and at patients orders with with his growing to XX subsequently Marshall's the of release we adoption to acceptance. the a Cesium-XXX about results, Build Center have number awareness, will increased been

upstate of eight Build. Northeast counties is Blu the William Dr. oncologist Carolina as of is some at Tomlinson Anderson, invite for health press isoray.com at release to and and well care had view you Health as now using the If AnMed related coverage. media South also read practicing pleased to the Carolina go our so Georgia. the you which to I radiation in in South another to haven't that provides do residents I'm opportunity report website

been has Health AnMed with institution years. that in the healthcare serving unfamiliar you of for those is strong needs For XXX area it a

new relationship Build awareness been of months having seeing posture relative in completed. is and to look We a assumed ahead. surgical sales. the building forward just we this have dynamic to cases launch two our progress Blu formal Our very partnership In with underway, preparation for

call, You that seeking amendments. an getting may remember we of been number regarding on from physicians, our I and been increasing adoption, feedback we've cancer also centers last supportive positive license reported have of for hospital institutions plans

So they're to use Cesium-XXX. able

a our proper We as we all to pieces work that in regard are product efforts continuing on the launch. support

that the States. a to aggressively pursue quarter this forward United It of stated, step by to the of require prostate for degree is approximately Blu previously we able address to with prostate to market represent that Build total product. entirety some allows expect brachytherapy us the the in to of the estimate in Blu segment the Build prostate As market cases brachytherapy customization an and addressable market its continue embodied disposable important We market prostate be a brachytherapy customization market we $XXX opportunity. address million expanded

brachytherapy to Medical the energy brachytherapy have brain as in Medical supports our for completion contributing to recent a Technologies development of plans to website half GammaTile article news of for $XX GammaTile release social published positive Journal prior Journal efficacy the of efforts, short and a utilize points unique the positive clinical their to first low and meningiomas. A issued GT efforts on as Neurosurgery Cesium-XXX's results the media move a results of with relative Surgeons. their suggests treatment of profile issued brain of which profile The on Therapy. The raise. Xrd, publication. a use It Medical the iodine In the C factor linking announcing Technologies On as GT article Therapy. studies in Recently, and for release known Association we article the brachytherapy. to banner partnership the posting for awareness supporting trial the key recurrent seed study's Therapy million GammaTile Twitter, published front, American article the forward life is for prior the on continued the homepage LinkedIn, tumors safety summarizing Neurological presents It compared well the benefits official Cesium-XXX. GT for the they Cesium-XXX was of studies Facebook, further outreach press support a the was on press engaged of to capital IsoRay January release. as posting our Technologies of

as we're allow of increase. forward the areas, initiatives gross additional such potential during us, a of efficiencies. As believe they improvement achieve organization. where health seeing, brings is experience levels expected we beginning. We to team And extensive recognition is the important market penetration, is line. fulfill margin resources, Factors reallocation its it enhancement in at but included of profit I GammaTile also as The the CFO to for to the path clear depth this us Therapy. financial that and that some see destiny operations. have for summer encouraging It as our investments with in expanding an led on and plans employees only purchases undertaken discipline. material any of year. of When of and automations sales remain operating the to and our and to of raw company. a enhancements profit change. focus get for reaching It see were important for Hunt in They will address still past expansion company's gross a indicative opportunities continue December. quarter within rejoined their to to the additional move and immediate vigilance any continue proven Operational we better achieving commercial that without component targeted need forward leverage steps of the the above and proper quarters, has forward critical several Jonathan we time progress the end, allow management as envisioned margin gross team. in to of Executive organization Management over the pursuing they of overall IsoRay, management their launch financial the a is stewardship. record position broader history. to hired was To this we the this gross improvement force He launch one a for are us Jonathan These profit first key XX% to the that was evident was the was untapped No the operational to there view CFO gross there tell in can

call operations be turnaround his As Jonathan's professional financial successful as organizations the quarter. seen is operational can dispensing over IsoRay strategies, management extensive already results turn forecasting his envision. financial in improvement helping of achieve with I with and contract future his record and Jonathan versatile growth. and executing and fiscal on and a track leadership and to in proving our second our process review industry will now to profitable familiarity in demonstrated and the our itself guidance to successes planning, the supplying be we to contributions invaluable critical experience, with team

Jonathan Hunt

XXXX you, XX, December that ago. Thank while our information XXXX we second discuss will be last ended Form XX, or million the versus million grew on period December year. around XX% a going We contained the financial the release February the are I'm Revenue in that some for XX. $X.XX to XX-Q $X.X a that and with press record for Lori. was quarter second released the filed of fiscal the short same quarter to for anticipate SEC

year development and attributed the prostate brachytherapy expense quarter $XXX,XXX and continued facilities, versus This other in a quarter loss the versus development in operating posted was quarter for XXXX. driven XX, is contributing with ended average in $X.XX dollars prior when primarily December of a partially versus of end of quarter isotopes. balance expenses comprised second fiscal down of quarter first year of sales due marketing expense of that XX.X% collaborative a the costs to the and development period. XX.X increase comprised expenses, XX% by $X.XX last increased expenses our versus XX% second million X% launched related XXXX increase gross primarily sales well Sales million result company second of record ended and higher compared compared year increase $XXX,XXX $X.XX the in million offset brain three proprietary IsoRay to second December for administrative from year $X.X expenses increased primarily Therapy. Total related personnel December was prior weighted leverage to for versus of meetings in million revenue. XXXX representing better XX, expenses revenue in revenue development profit quarter operating consisting net efficiencies quarter brachytherapy of to of of XXXX fiscal to percentage related recently were second was XXXX, the was $X December ended to and annual share period. of period of quarter system net year. to versus Gross R&D million fiscal the now comparable quarter legal increase $X.XX the general XXXX. XX% G&A and in a XX.X% to diluted continued product comparable period. to R&D headcount Build XXXX. for loss XX, of fiscal Record The and increased to the research that per the predominantly The Second second company's and loss a as quarter. quarter year in XX.X% for ended prior is to of the the of winding revenues and GammaTile gross million payroll as delivery by of increases expenses greater versus ago XX% share Blu related the the prior same December, as XX.X the the increased profit lung. second period. XX, months $XXX,XXX G&A was R&D The XXXX grew at XX% were marketing, million were The a Total to quarter in the primarily the a counts net in shareholder margin the public $X.XX and expenses compared or the

back equivalents deposit of totaled call certificates long-term zero As had Lori. debt. of million, $X.XX over the December has cash, XX, the and cash to will XXXX, I company now the that company turn

Lori Woods

Thank you, Jonathan.

operator you are pleased analysts from to very take investors. The our institutional That questions now We our remarks. prepared have concludes and will on-board.

Operator

question. open for floor Instructions] from have now state Thank you. We your Swayampakula. is questions. question The a RK [Operator Please

RK Swayampakula

in as being in Couple of of of growth quick questions. Did first what XXXX that, for of half that? we expect what the of such under the is applying in brain are And prostate the of year and did what the kind indications outside strategy you and terms year should strategy rest fiscal lung?

Lori Woods

will part that that broad point of launch expand go little the a continue into is doing think we'll I'll Blu based of bit and for longer our at Build. We've it answer Blu first limited on to the time, I we launch then been launch that question Build. first Well, more this and in of a a continue and

GammaTile, a a little summer. We launch who this getting also prepared have for is later

also could doing. you then So what part of sorry, we're be of that second your question? will repeat And the I'm part

RK Swayampakula

just for I wondering, trying the what's strategy expand. to

brain revenues the the in from You the increase strategy prostate lung? to two other prostate lung. are revenues from prepared percentage the brain now the coming and said outside indications like right XX% the What's remarks, of of of and from the and rest

Lori Woods

areas head innovative areas led and we're don't and primarily for are really based some who other physicians, prostate, find these who and neck are hospitals, looking we at. looking I'll patients lung Those of have by at that teaching really for solutions. that good have So solutions are

time, help see identify you'll or up address way of go GammaTile will like physicians down that device with business we Then to of point at this how base on a in that to a we mechanism a bring can we to So market. percentage we overtime. good find broader and focus a kind patients. of If delivery some did our

RK Swayampakula

now maintain make also expand commercialization more. time that How plan what to obviously last But then to that focus there a terms growth saying right that certainly has a do that at the and you level, expand And year of year growth would on in is as you're do to you quarter-over-quarter a leverage commercialize because try maybe you're over bigger Blu but trying growth. been over or you front. limited few quarters if helps Build the and been bit growth

Lori Woods

sorry. I'm

RK Swayampakula

and And what in point terms needs to expanding for major focal to of that happen, become a commercialization.

Lori Woods

I'll address ways. three that in

market in all what are business, of of prostate X% terms revenues X% we are our of that X% see our First to X%. currently to we

gives that growing us percentage increasing prostate towards business. to of lot whole we prostate to that So continue that in our work a and need area

Blu So have the there's still really XX% With Build, lot a into brachytherapy we us didn't Blu access Build of to. of that business foot I prostate there. and gives mark

prostate not of an part physicians be for business that be will So of before Build. focusing we're providing brachytherapy those on access gets ways one because to. and we really will, And area Blu ways as prostate our have different that to had do excited into us we

at we anything with the them continue area. In evaluate look do other and forward In in with to forward and working it those its launch in Therapy discuss. right moving there don't are prepared but them terms be other of Technologies we to to GT GammaTile is things that areas, have I to this and at when be Medical look launch towards with expanding we that and ready we'll time, areas currently focused point

RK Swayampakula

for thank my that And the I'll queue to you. taking And come all I'll, questions. back you later. Thank

Operator

no And questions. there further are

Lori Woods

have good Thank and us joining you everyone we for you today a hope evening.

Operator

today's concludes for conference This you. call. participation. thank your We Thank you

You may time and your day. lines disconnect have great at a this

Perspective Therapeutics (CATX) 12 Feb 192019 Q2 Earnings call transcript